*August 2021* Attention All Resisters! A new clinical trial finder, Medifind, is now live, which may help EGFR Resisters to quickly narrow down
About firstname.lastname@example.orgThis author has not yet filled in any details.
So far email@example.com has created 176 blog entries.
*June 2021* Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for firstname.lastname@example.orgT18:27:18-07:00
*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation
*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung
*July 2021* Written by Tess Taft, MSW, LICSW, and oncology psychotherapist.© “I feel like I’m doing something terrible to
Randomized phase III trial of aumolertinib vs gefitinib as 1st line treatment for EGFR exon 19 del or L858R email@example.comT17:57:39-07:00
*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor
*June 2021* Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve
*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated
*June 2021* The EGFR Resisters is thrilled to announce a new multi-year research partnership with Lung Cancer Research Foundation (LCRF)!
Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Reportlaurabbook@gmail.com2021-06-24T12:23:55-07:00
*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated